Results 11 to 20 of about 5,889,184 (390)
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
New England Journal of Medicine, 2021 BACKGROUND Metastatic castration-resistant prostate cancer remains fatal despite recent advances. Prostate-specific membrane antigen (PSMA) is highly expressed in metastatic castration-resistant prostate cancer.
O. Sartor +19 more
semanticscholar +1 more source
Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology.
The Journal of the National Comprehensive Cancer Network, 2023 The NCCN Guidelines for Prostate Cancer provide a framework on which to base decisions regarding the workup of patients with prostate cancer, risk stratification and management of localized disease, post-treatment monitoring, and treatment of recurrence ...
E. Schaeffer +37 more
semanticscholar +1 more source
Prostate Cancer Review: Genetics, Diagnosis, Treatment Options, and Alternative Approaches
Molecules, 2022 Simple Summary Prostate cancer affects men of all racial and ethnic groups and leads to higher rates of mortality in those belonging to a lower socioeconomic status due to late detection of the disease.
M. Sekhoacha +5 more
semanticscholar +1 more source
Journal of Clinical Oncology, 2021 PURPOSE This study investigates whether focal boosting of the macroscopic visible tumor with external beam radiotherapy increases biochemical disease-free survival (bDFS) in patients with localized prostate cancer. PATIENTS AND METHODS In the phase III,
L. Kerkmeijer +13 more
semanticscholar +1 more source
NCCN Guidelines Insights: Prostate Cancer, Version 1.2021.
The Journal of the National Comprehensive Cancer Network, 2021 The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a prostate cancer diagnosis and include management options for localized, regional, and metastatic disease.
E. Schaeffer +31 more
semanticscholar +1 more source
BMC Urology, 2022 Background To report the feasibility, oncological and functional outcomes of salvage robot-assisted radical prostatectomy (sRARP) for recurrent prostate cancer (PCa) after irreversible electroporation (IRE).
Alexandar Blazevski +11 more
doaj +1 more source
Longitudinal trends in prostate cancer incidence, mortality, and survival of patients from two Shanghai city districts: a retrospective population-based cohort study, 2000-2009. [PDF]
, 2014 BackgroundProstate cancer is the fifth most common cancer affecting men of all ages in China, but robust surveillance data on its occurrence and outcome is lacking. The specific objective of this retrospective study was to analyze the longitudinal trends
Deng, Haiju +5 more
core +3 more sources
Components of cell-matrix linkage as potential new markers for prostate cancer [PDF]
, 2011 Prostate cancer is one of the most common tumor diseases worldwide. Often being non-aggressive, prostate tumors in these cases do not need immediate treatment.
Eble, Johannes Andreas, Navdaev, Alexey
core +2 more sources
Increased survival with enzalutamide in prostate cancer after chemotherapy.
New England Journal of Medicine, 2012 BACKGROUND Enzalutamide (formerly called MDV3100) targets multiple steps in the androgen-receptor-signaling pathway, the major driver of prostate-cancer growth.
H. Scher +19 more
semanticscholar +1 more source
BMC Cancer, 2018 Background For the expanding population of bladder cancer survivors in Korea, the development of subsequent cancers is a significant concern. Here, we provide the second primary cancer incidence rates and types in Korean patients with bladder cancer ...
Whi-An Kwon +10 more
doaj +1 more source